Dr. Ahmed Alwabari


Consultant oncology KFSHD

09:45 –10:30

Friday 3-5-2024 Day 1

Role of anthracyclines in early breast cancer

  • When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer

    When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer

Moderator:Dr. Meteeb Alfohaidi



Friday 3-5-2024 Day 1

Genomic tools in breast cancer

  •  chemotherapy in high risk lobular/mucinous BC?
  • Neoadjuvant therapy in premenopausal patients with lobular BC?
    Adjuvant therapy with node negative and node positive lobular BC?
    Adjuvant therapy in luminal BC with RS 16-25?
    Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours??
  • Oncotype DX and selection of neoadjuvant  hormonal vs chemotherapy  therapy
  • Role of interval Ki67 assessment with neoadjuvant  hormonal therapy

Moderator: Ahmed Alshehri